Patient and External Quality Assessment Samples Demonstrate Similar Bias Between Manufacturers in Titer of Antibodies to Nuclear Antigens: Implications for Commutability

Arch Pathol Lab Med. 2021 Aug 1;145(8):919-920. doi: 10.5858/arpa.2021-0060-LE.

Authors

Susan L Fink¹, Michael A Linden², Mark H Wener^{1

3}

Affiliations

¹ Department of Laboratory Medicine and Pathology, University of Washington, Seattle.
² Department of Laboratory Medicine and Pathology, University of Minnesota Medical Center, Minneapolis.
³ Division of Rheumatology in the Department of Medicine, University of Washington, Seattle.

No abstract available

Publication types

Comparative Study
Letter

MeSH terms

Antibodies, Antinuclear / blood*
Biomarkers / blood
Calibration
Fluorescent Antibody Technique, Indirect / standards*
Humans
Lupus Erythematosus, Systemic / blood
Lupus Erythematosus, Systemic / diagnosis*
Lupus Erythematosus, Systemic / immunology
Observer Variation
Predictive Value of Tests
Quality Control
Quality Indicators, Health Care / standards*
Reagent Kits, Diagnostic / standards*
Reference Standards
Reproducibility of Results
Scleroderma, Systemic / blood
Scleroderma, Systemic / diagnosis*
Scleroderma, Systemic / immunology

Substances

Antibodies, Antinuclear
Biomarkers
Reagent Kits, Diagnostic

Grants and funding